Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteamine SCHEMBL1270405 | 0.85 | — | — | |
| Cysteamine SCHEMBL16369 | 0.85 | — | — | |
| Cysteamine SCHEMBL8340751 | 0.85 | TSHR (1.00) | CYP3A4TSHRALDH1A1LMNAMAPT | |
| Cysteamine SCHEMBL2357943 | 0.80 | — | — | |
| Cysteamine SCHEMBL21826826 | 0.80 | — | — | |
| Cysteamine SCHEMBL25318894 | 0.80 | — | — | |
| Cysteamine SCHEMBL21826833 | 0.80 | — | — | |
| Cysteamine SCHEMBL21981247 | 0.80 | — | — | |
| Cysteamine SCHEMBL25327317 | 0.80 | — | — | |
| Cysteamine SCHEMBL7624444 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | claimed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | claimed |
| WO-2012036962-A2 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012036962-A2 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-3972890-A | ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | IAPP, SELENOI, SCLY | CYP3A4 3951/4885TSHR 362/4885ALDH1A1 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.